TRENDSPOTTER: Corporate Venture Capital May Rival Traditional VC Firms in -omic Funding | GenomeWeb

Today in Europe there is a growing trend toward establishing venture-capital funds that are sourced exclusively by a major corporation. 

Some big pharmaceutical firms have recognized the potential rewards for nurturing small start-up firms—namely, novel IP—and have begun putting together modest funds of their own to pursue them. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.